NeoGenomics, Inc. (NEO) Stock: Do Analysts Think You Should Accumulate?

Wall Street is positive on NeoGenomics, Inc. (NEO). On average, analysts give the stock a Strong Buy rating. The average price target is $51.625, which means analysts expect the stock to gain by 38.37% over the next twelve months. That average ranking earns the stock an Analyst Rating of 59, which is better than 59% of stocks based on data compiled by InvestorsObserver.

Wall Street analysts are rating NEO a Strong Buy today. Find out what this means to you and get the rest of the rankings on NEO!

See Full NEO Report

Why are Analyst Ratings Important?

Though analyst projections should not be your only resource when determining your position on a stock, it can be a very useful tool. Analysts follow sectors/industries in-depth and tend to know how local and global conditions tend to affect demand and prices. Many analysts even participate in conference calls where they can get information to better make sense of the numbers. InvestorsObserver averages the ratings provided by analysts and then ranks their score as a percent against the market. This allows you to compare stocks in a more comprehensive fashion than with the typical buy/sell/hold ranking.

What's Happening With NeoGenomics, Inc. Stock Today?

NeoGenomics, Inc. (NEO) stock has risen 0.08% while the S&P 500 has fallen -0.36% as of 10:28 AM on Wednesday, Nov 24. NEO is higher by $0.03 from the previous closing price of $37.28 on volume of 139,740 shares. Over the past year the S&P 500 is higher by 28.56% while NEO has fallen -17.29%. NEO earned $0.35 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 107.9. Click Here to get the full Stock Report for NeoGenomics, Inc. stock.